Glycemic/Insulinemic Effects of Fresh Mango as a Sugar Substitute in Realistic Breakfasts

This study is looking at how fresh mango, when used instead of table sugar in breakfast meals, affects your blood sugar and insulin levels. Researchers want to see if replacing table sugar with mango in both oat-based and corn flake-based breakfasts can lead to healthier responses in your body. They are also interested in how these meals affect your blood vessels. You might be able to join if you are a healthy adult between 18 and 45 years old, with a BMI between 18.5 and 35.0 kg/m2, and do not have certain health conditions like diabetes or heart disease. The study aims to enroll 24 participants, but its current recruitment status is unclear.

Study design
This is an interventional study with 24 healthy participants. You would try four different breakfast meals in a randomized crossover design, meaning the order of meals is random and you try all of them.
What's involved
You will complete four meal trials. At each trial, you'll have an IV catheter inserted for blood samples, and your brachial artery (in your arm) will be measured before and after eating. You'll also complete surveys about how you liked the meal and how full you feel.
Compensation
Not stated in the trial record.
Follow-up
Your glucose and insulin levels will be measured throughout the study, up to 1.5 years, and flow-mediated dilation (a measure of blood vessel health) will be measured up to 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07045051

Glycemic/Insulinemic Effects of Fresh Mango as a Sugar Substitute in Realistic Breakfasts.

Recruiting
NAAges 18–45Interventional
Ball State University
~24 participants
Updated 2025-07-01 on ClinicalTrials.gov
What's tested:Low-Glycemic Breakfast Containing Oats and MangoHigh-Glycemic Breakfast Containing Cereal and MangoLow-Glycemic Breakfast Containing Oats and Table SugarHigh-Glycemic Breakfast Containing Cereal and Table Sugar

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Glucose
Measured over Through study completion, up to 1.5 years.
+2 more outcomes measured
Healthy Participants
1 sites across 1 states
Indiana1
  • Bryant Keirns, PhD · PRINCIPAL_INVESTIGATOR · Ball State University

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 - 45 years.
Body mass index between 18.5-35.0 kg/m2
Not pregnant (females only)
Not postmenopausal (females only).
Not been diagnosed with cardiovascular disease.
Not been diagnosed with a cardiometabolic conditions (e.g., type 2 diabetes)
Not been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease).
Does not regularly take anti-inflammatory drugs (more than 2x week).
Does not use glucose-lowering drugs (e.g., metformin)
Does not use lipid-lowering drugs (e.g., statins)
Does not use tobacco products or any illicit drugs.
Does not have a pacemaker.
Can consume mango, wheat, gluten, and milk.
Can stay in a supine position in the dark for at least ten minutes.

Exclusion

Not between the ages of 18-45
Body mass index \< 18.5 kg/m2 or \>35.0 kg/m2
Pregnant (females only)
Postmenopausal status (females only).
Been diagnosed with cardiovascular disease.
Been diagnosed with a cardiometabolic conditions (e.g., type 2 diabetes)
Been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease).
Regularly take anti-inflammatory drugs (more than 2x week).
Uses glucose-lowering drugs (e.g., metformin)
Uses lipid-lowering drugs (e.g., statins)
Uses tobacco products or any illicit drugs.
Have a pacemaker.
Allergic to mango, wheat, gluten, and/or milk.
Unable to lay in supine position in the dark for at least ten minutes.
  • GlucoseThrough study completion, up to 1.5 years.

    The investigators will measure glucose at baseline and .5-, 1-, 2-, and 3-hours after each meal. These measurements will take place immediately and a complete dataset will be compiled upon study completion.

  • InsulinThrough study completion, up to 1.5 years.

    The investigators will measure insulin at baseline and .5- 1-, 2-, and 3-hours after each meal containing. These measurements will take place immediately and a complete dataset will be compiled upon study completion.

  • Flow-mediated DilationThrough study completion, up to 1 year.

    The investigators will measure FMD at baseline and 1-, 2-, and 3-hours after the meal. These measurements will take place immediately and a complete dataset will be compiled upon study completion.